نتایج جستجو برای: everolimus

تعداد نتایج: 3889  

2017
Wobke E. M. van Dijk Menno A. M. H. Vergeer Joop E. Arends

INTRODUCTION The incidence of hepatitis E (HEV) genotype 3 is rising in developed countries. HEV infections are usually self-limiting, but can become chronic in immunocompromised patients. This might lead to rapid fibrosis development even resulting in cirrhosis. Chronic HEV is mainly described in patients after solid-organ or hematological transplantations. We present the first case of HEV inf...

2013
James Signorovitch Elyse Swallow Evan Kantor Xufang Wang Judith Klimovsky Tomas Haas Beth Devine Peter Metrakos

BACKGROUND Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged overall survival compared to placebo. This study aimed to indirectly compare overall and progression-free among everolimus, sunitinib and placebo across separate randomized trials. ...

Journal: :Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2014
Lily Lewis Matthew Taylor Yessentayeva Suriya Ertugyrovna Nurgaziev Kuanysh Shadybayevich Smagulova Kaldygul Kabakovna Abdrakhmanov Ramil Zufarovich

OBJECTIVE The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women. RESEARCH DESIGN AND METHODS A cumulative cohort model was developed to estimate the 5-year costs associated with introducing everolimus to the Kazakh health...

Journal: :Revista espanola de cardiologia 2014
Manuel Pan Francesco Burzotta Carlo Trani Alfonso Medina Jose Suárez de Lezo Giampaolo Niccoli Miguel Romero Italo Porto Francisco Mazuelos Antonio Maria Leone Pedro Martín Valentina Coluccia Javier Suárez de Lezo Soledad Ojeda Filippo Crea

INTRODUCTION AND OBJECTIVES To compare the 3-year incidence of major events in patients with bifurcation lesions treated with provisional sirolimus-eluting stents vs everolimus-eluting stents. METHODS A pooled analysis of 2 prospective randomized trials with similar methodology (SEAside and CORpal) was performed. In these trials, 443 patients with bifurcation lesions were randomly assigned to...

2017
Benrui Lin Lan Zhang Dinuo Li Hongzhi Sun

We investigated the role of the transcriptional mediator subunit 23 (MED23) in everolimus drug resistance, invasion and metastasis during breast cancer treatment and its molecular mechanism. We also evaluated the endocrinotherapy and prevention method for breast cancer. Breast cancer cell strains were established that can continuously express MED23, as well as inducible MED23-shRNA expression p...

Journal: :Circulation. Cardiovascular interventions 2014
Anwer Habib Vinit Karmali Michael C John Rohini Polavarapu Gaku Nakazawa Kim Pachura Talina Davis Frank D Kolodgie Renu Virmani Aloke V Finn

BACKGROUND Preclinical evaluation of the vascular response of drug-eluting stents is limited especially in the setting of diabetes mellitus preventing the evaluation of changes in drug-eluting stent design and eluted drugs after clinical use. METHODS AND RESULTS Cultured human aortic endothelial cells were used to assess the differences between sirolimus and its analog, everolimus, in the set...

2017
Masahiro Matsuki Yusuke Adachi Yoichi Ozawa Takayuki Kimura Taisuke Hoshi Kiyoshi Okamoto Osamu Tohyama Kaoru Mitsuhashi Atsumi Yamaguchi Junji Matsui Yasuhiro Funahashi

The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC). We investigated potential mechanisms underlying the antitumor activity of the combination treatment in preclin...

Journal: :Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2018
Hiroshi Nomoto Hideaki Miyoshi Tomonori Sekizaki Tatsuya Atsumi

We read with great interest the report of elevated serum carcinoembryonic antigen (CEA) following everolimus administration,1) in which it was reported that everolimus treatment for renal cell carcinoma with lung metastasis caused pulmonary ground-glass opacities accompanied by elevated serum CEA. Furthermore, interrupting everolimus resulted in improvements of both lung shadows and elevated CE...

Journal: :The Lancet 2016
Jacqueline A French John A Lawson Zuhal Yapici Hiroko Ikeda Tilman Polster Rima Nabbout Paolo Curatolo Petrus J de Vries Dennis J Dlugos Noah Berkowitz Maurizio Voi Severine Peyrard Diana Pelov David N Franz

BACKGROUND Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. We assessed the efficacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in t...

2012
Laia Rosich Sílvia Xargay-Torrent Elías Campo Dolors Colomer

Purpose: Mantle cell lymphoma (MCL) is an aggressive B-lymphoid neoplasm with poor response to conventional chemotherapy and short survival. The phosphatidylinositol 3-kinase/Akt/mTOR survival pathway is constitutively activated in MCL cells, thereby making the mTOR inhibition an attractive therapeutic strategy. The first clinical studies of everolimus (RAD001), an mTOR inhibitor, in relapsed M...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید